About KPBMA

Yunhong Noh President of KPBMA
Since the establishment of the first modern pharmaceutical company in 1897, the Korean pharmaceutical industry has grown into a vital pillar of the national economy, achieving continuous innovation despite numerous domestic and global challenges.
As a result, high-quality Korean medicines are now supplied to around 200 countries worldwide. Notably, Korea recently achieved a historic milestone with the development of its first global blockbuster drug. The country is also taking a prominent position in innovative drug development and technology licensing with major global pharmaceutical companies, establishing itself as a key partner on the international stage.
Korea’s research and development (R&D) capabilities are now on par with the world’s leading nations. Korean pharmaceutical companies currently hold over 3,000 drug development pipelines—ranking third globally—and are playing an active role in developing next-generation technologies such as AI-driven drug discovery, DACs, ADCs, TPDs, and CGTs.
Recognizing the strategic importance of the pharmaceutical and biotech sector, the Korean government has been actively supporting the industry through a wide range of policy initiatives. These include fostering innovative pharmaceutical companies and promoting open innovation. Thanks to strong collaboration between the public and private sectors, Korea's pharmaceutical industry continues to grow steadily, with the country expected to rank among the global top ten by 2030.
Founded in 1945 with the mission to advance public health and industrial development, the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) celebrates its 80th anniversary this year. Over the past eight decades, KPBMA has played a central role in improving regulatory frameworks, strengthening R&D capabilities, and supporting global market expansion for Korean companies.
Looking ahead, KPBMA will continue to strengthen collaboration with global partners to contribute to the advancement of public health worldwide and lead the next leap forward for the Korean pharmaceutical and biotech industry.